Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy

被引：4
作者：
Deng, Xiyun [1 ]
Zheng, Chanjuan [1 ]
Tang, Faqing [2 ,3 ]
Rosol, Thomas J. J. [4 ]
Shao, Zhi-Ming [5 ,6 ]
机构：
[1] Hunan Normal Univ, Key Lab Translat Canc Stem Cell Res, Sch Med, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Sch Med, Hunan Key Lab Oncotarget Gene, Clin Lab,Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Affiliated Canc Hosp, Hunan Key Lab Oncotarget Gene, Xiangya Sch Med, Changsha, Hunan, Peoples R China
[4] Ohio Univ, Heritage Coll Osteopath Med, Dept Biomed Sci, Athens, OH USA
[5] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Key Lab Breast Canc Shanghai,Dept Breast Surg, Shanghai, Peoples R China
[6] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金：
中国国家自然科学基金;
关键词：
triple-negative breast cancer; heterogeneity; tumor microenvironment; targeted therapy; clinical outcomes;
D O I：
10.3389/fonc.2022.1026566
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 18 条
[1]   Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel? [J].
Bai, Xupeng ;
Ni, Jie ;
Beretov, Julia ;
Graham, Peter ;
Li, Yong .
CANCER LETTERS, 2021, 497 :100-111
[2]   Molecular alterations in triple-negative breast cancer-the road to new treatment strategies [J].
Denkert, Carsten ;
Liedtke, Cornelia ;
Tutt, Andrew ;
von Minckwitz, Gunter .
LANCET, 2017, 389 (10087) :2430-2442
[3]   Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment [J].
Garrido-Castro, Ana C. ;
Lin, Nancy U. ;
Polyak, Kornelia .
CANCER DISCOVERY, 2019, 9 (02) :176-198
[4]   A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases [J].
Huang, Richard S. P. ;
Haberberger, James ;
Severson, Eric ;
Duncan, Daniel L. ;
Hemmerich, Amanda ;
Edgerly, Claire ;
Ferguson, Naomi Lynn ;
Williams, Erik ;
Elvin, Julia ;
Vergilio, Jo-Anne ;
Killian, Jonathan Keith ;
Lin, Douglas I. ;
Tse, Julie ;
Hiemenz, Matthew ;
Owens, Clarence ;
Danziger, Natalie ;
Hegde, Priti S. ;
Venstrom, Jeffrey ;
Alexander, Brian ;
Ross, Jeffrey S. ;
Ramkissoon, Shakti H. .
MODERN PATHOLOGY, 2021, 34 (02) :252-263
[5]   Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients [J].
Liu, Jieqiong ;
Li, Ying ;
Li, Qian ;
Liang, Dandan ;
Wang, Quanren ;
Liu, Qiang .
BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) :687-697
[6]   Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression [J].
Liu, Rong ;
Shi, Peiguo ;
Nie, Zhi ;
Liang, Huichun ;
Zhou, Zhongmei ;
Chen, Wenlin ;
Chen, Haijun ;
Dong, Chao ;
Yang, Runxiang ;
Liu, Suling ;
Chen, Ceshi .
THERANOSTICS, 2016, 6 (04) :533-544
[7]   miR-30a/SOX4 Double Negative Feedback Loop is modulated by Disulfiram and regulates EMT and Stem Cell-like properties in Breast Cancer [J].
Liu, Zijian ;
Mi, Mi ;
Zheng, Xin ;
Zhang, Caijiao ;
Zhu, Fang ;
Liu, Tao ;
Wu, Gang ;
Zhang, Liling .
JOURNAL OF CANCER, 2021, 12 (16) :5053-5065
[8]   PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers [J].
Luo, Linjie ;
Keyomarsi, Khandan .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (06) :607-631
[9]   Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan [J].
McGuinness, Julia E. ;
Kalinsky, Kevin .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) :903-913
[10]   Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer [J].
Mir, Manzoor A. ;
Qayoom, Hina ;
Mehraj, Umar ;
Nisar, Safura ;
Bhat, Basharat ;
Wani, Nissar A. .
CURRENT CANCER DRUG TARGETS, 2020, 20 (08) :586-602
12